[1]吴静,冉兴无.糖尿病下肢动脉病变的早期筛查与规范化管理[J].国际内分泌代谢杂志,2021,41(06):587-590.[doi:10.3760/cma.j.cn121383-20210922-09064]
　Wu Jing,Ran Xingwu..Early screening and standardized management of artery disease in diabetic lower extremity[J].International Journal of Endocrinology and Metabolism,2021,41(06):587-590.[doi:10.3760/cma.j.cn121383-20210922-09064]
点击复制

糖尿病下肢动脉病变的早期筛查与规范化管理()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
587-590
栏目:
专家论坛
出版日期:
2021-12-20

文章信息/Info

Title:
Early screening and standardized management of artery disease in diabetic lower extremity
作者:
吴静; 冉兴无
四川大学华西医院内分泌代谢科,糖尿病足诊治中心,创面修复创新中心,成都 610041
Author(s):
Wu Jing;  Ran Xingwu.
Innovation Center for Wound Repair, Diabetic Foot Care Center, Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, China
关键词:
糖尿病下肢动脉病变;  动脉粥样硬化;  筛查;  管理
Keywords:
Diabetic lower extremity arterial disease;  Atherosclerosis;  Screening;  Management
DOI:
10.3760/cma.j.cn121383-20210922-09064
摘要:
糖尿病下肢动脉病变是糖尿病患者常见的并发症之一,其动脉粥样硬化病理机制导致极高的心脑血管事件和下肢截肢风险,造成残疾、死亡和严重的社会经济负担。早期筛查是改善疾病预后的重要环节,结合全面的血管病变评估结果推定诊断。临床疑诊患者应立即完善全面的病情评估,并给予规范化管理。本文就糖尿病下肢动脉病变诊疗策略的临床研究进展进行综述,以加强疾病的综合管理水平。
Abstract:
Diabetic lower extremity arterial disease is one of the common complications of diabetic patients. Its pathological mechanism of atherosclerosis makes a high risk of cardiovascular, cerebrovascular events and lower extremity amputation, causing disability, death and severe socioeconomic burden. Early screening is an important part of improving prognosis, and the timely diagnosis is presumed based on the comprehensive assessment of vascular disease. Clinical suspected patients should do an overall condition assessment immediately, then the standardized management should be given. The review summarizes the findings of the latest researches on diagnosis and treatment of diabetic lower extremity arterial disease to strengthen the level of comprehensive disease management.

参考文献/References:

[1] Aboyans V,Ricco JB,Bartelink MEL,et al.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases,in collaboration with the European Society for Vascular Surgery(ESVS)[J].Rev Esp Cardiol(Engl Ed),2018,71(2):111.DOI:10.1016/j.rec.2017.12.014.
[2] Essa H,Torella F,Lip GYH.Current and emerging drug treatment strategies for peripheral arterial disease[J].Expert Opin Pharmacother,2020,21(13):1603-1616.DOI:10.1080/14656566.2020.1774556.
[3] Fowkes FGR,Rudan D,Rudan I,et al.Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010:a systematic review and analysis[J].Lancet,2013,382(9901):1329-1340.DOI:10.1016/S0140-6736(13)61249-0.
[4] Zhang X,Ran X,Xu Z,et al.Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk:a prospective,multicenter,cross-sectional study[J].J Diabetes Complications,2018,32(2):150-156.DOI:10.1016/j.jdiacomp.2017.10.003.
[5] 张梦丹,朱凌燕,刘玉.糖尿病性下肢血管病变发病机制的研究进展[J].临床合理用药杂志,2021,14(6):174-177.DOI:10.15887/j.cnki.13-1389/r.2021.06.070
[6] Barnes JA,Eid MA,Creager MA,et al.Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease[J].Arterioscler Thromb Vasc Bio,2020,40(8):1808-1817.DOI:10.1161/ATVBAHA.120.314595.
[7] Narula N,Olin JW,Narula N.Pathologic disparities between peripheral artery disease and coronary artery disease[J].Arterioscler Thromb Vasc Biol,2020,40(9):1982-1989.DOI:10.1161/ATVBAHA.119.312864.
[8] Spannbauer A,Chwaa M,Ridan T,et al.Intermittent claudication in physiotherapists' practice[J].Biomed Res Int,2019,2019:2470801.DOI:10.1155/2019/2470801.
[9] 中华医学会糖尿病学分会.2型糖尿病患者合并下肢动脉病变的筛查及管理规范[J].中华糖尿病杂志,2013,5(2):8288.DOI:10.3760/cma.j.issn.1674-5809.2013.02.006
[10] American Diabetes Association.11.Microvascular complications and foot care:standards of medical care in diabetes-2019[J].Diabetes Care,2019,42(Suppl 1):S124-138.DOI:10.2337/dc19-S011.
[11] Donohue CM,Adler JV,Bolton LL.Peripheral arterial disease screening and diagnostic practice:a scoping review[J].Int Wound J,2020,17(1):32-44.DOI:10.1111/iwj.13223.
[12] Forsythe RO,Apelqvist J,Boyko EJ,et al.Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus:a systematic review[J].Diabetes Metab Res Rev,2020,36 Suppl 1:e3277.DOI:10.1002/dmrr.3277.
[13] Jansen SC,Abaraogu UO,Lauret GJ,et al.Modes of exercise training for intermittent claudication[J].Cochrane Database Syst Rev,2020,8(8):CD009638.DOI:10.1002/14651858.
[14] Lin C,Zhu X,Cai X,et al.SGLT2 inhibitors and lower limb complications:an updated meta-analysis[J].Cardiovasc Diabetol,2021,20(1):91.DOI:10.1186/s12933-021-01276-9.
[15] Höbaus C,Herz CT,Wrba T,et al.Peripheral arterial disease and type 2 diabetes:older patients still exhibit a survival benefit from glucose control[J].Diab Vasc Dis Res,2020,17(2):1479164120914845.DOI:10.1177/1479164120914845.
[16] Fudim M,Hopley CW,Huang Z,et al.Association of hypertension and arterial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease:the EUCLID trial[J].Circ Cardiovasc Qual Outcomes,2020,13(9):e006512.DOI:10.1161/CIRCOUTCOMES.120.006512.
[17] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
[18] Schwartz GG,Steg PG,Szarek M,et al.Peripheral artery disease and venous thromboembolic events after acute coronary syndrome:role of lipoprotein(a)and modification by alirocumab:prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial[J].Circulation,2020,141(20):1608-1617.DOI:10.1161/CIRCULATIONAHA.120.046524.

相似文献/References:

[1]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
　Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[2]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
　Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[3]缪莹,万沁.Nrf2/ARE通路与糖尿病相关动脉粥样硬化[J].国际内分泌代谢杂志,2017,37(03):203.[doi:10.3760/cma.j.issn.1673-4157.2017.03.016]
　Miao Ying,Wan Qin..Nrf2/ARE signal pathway and diabetes associated atherosclerosis[J].International Journal of Endocrinology and Metabolism,2017,37(06):203.[doi:10.3760/cma.j.issn.1673-4157.2017.03.016]
[4]周赛君,赵建彤,叶翠,等.自然杀伤细胞与2型糖尿病[J].国际内分泌代谢杂志,2017,37(04):274.
　Zhou Saijun,Zhao Jiantong,Ye Cui,et al.Natural killer cells and type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2017,37(06):274.
[5]谭璐 闫彩凤 曾纯 陈晴 宫祎慧.成人隐匿性自身免疫性糖尿病患者的脂代谢 特点及其与颈动脉粥样硬化的关系[J].国际内分泌代谢杂志,2019,39(03):160.[doi:10.3760/cma.j.issn.1673-4157.2019.03.004]
　Tan Lu,Yan Caifeng,Zeng Chun,et al.Lipid metabolism and its association with carotid atherosclerosis in patients with latent autoimmune diabetes mellitus in adults[J].International Journal of Endocrinology and Metabolism,2019,39(06):160.[doi:10.3760/cma.j.issn.1673-4157.2019.03.004]
[6]袁和菊 刘晶 李娜 刘晓霞 李兴.Vaspin对2型糖尿病大血管病变的保护作用[J].国际内分泌代谢杂志,2019,39(04):261.[doi:10.3760/cma.j.issn.1673-4157.2019.04.011]
　Yuan Heju,Liu Jing,Li Na,et al.Protective effect of vaspin on macrovascular disease in type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2019,39(06):261.[doi:10.3760/cma.j.issn.1673-4157.2019.04.011]
[7]何桥玲 陈桂兰 陈家琪 张振 孙嘉 陈宏.白脂素在2型糖尿病发生及发展中的作用[J].国际内分泌代谢杂志,2020,40(04):267.[doi:10.3760/cma.j.issn.1673-4157.2020.04.012]
　He Qiaoling,Chen Guilan,Chen Jiaqi,et al.Roles of asprosin in the occurence and development of type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(06):267.[doi:10.3760/cma.j.issn.1673-4157.2020.04.012]
[8]李春睿,吴燕,徐书杭,等.SGLT2抑制剂在2型糖尿病合并阿尔茨海默病中作用的研究进展[J].国际内分泌代谢杂志,2023,43(06):496.[doi:10.3760/cma.j.cn121383-20220729-07064]
　Li Chunrui,Wu Yan,Xu Shuhang,et al.Research progress of the effect of sodium glucose cotransporter 2 inhibitors in Alzheimer's disease[J].International Journal of Endocrinology and Metabolism,2023,43(06):496.[doi:10.3760/cma.j.cn121383-20220729-07064]

备注/Memo

备注/Memo:
基金项目:四川省科学技术厅科研项目(2021JDKP0044); 四川大学华西医院学科发展1.3.5工程项目(ZYGD18025)
通信作者:冉兴无,Email:ranxingwu@163.com
更新日期/Last Update: 2021-12-10